Abogen has been invited to speak at the 6th mRNA-Based Therapeutics Summit, taking place from July 20 to 22 2026, in Boston, Massachusetts.

Dr. Iain McFadyen, Chief AI Officer of Abogen, will share how AI/machine learning serves as a core engine across the end-to-end mRNA value chain, comprehensively driving innovation from sequence design, delivery optimization, protein design to automated and digital manufacturing.

Abogen's Speaking Session

Topic: The Next Frontier for mRNA Therapeutics - AI Applications in Design, Delivery & Manufacturing

Date & Time: July 20, 2026 – 9:00 AM (EDT)

Highlights:

① Using ML/AI in mRNA sequence design

② Applying ML/AI in delivery design and optimization

③ Leveraging ML/AI in protein design

④ Automation, process optimization, and digitization - Enabling efficiency but also feeding the Design-Build-Test-Learn virtuous cycle

About 6th mRNA-Based Therapeutics Summit

As a premier platform uniting frontier breakthroughs, strategic partnerships, and industry insights, this year's summit will focus on ground-breaking data and emerging assets. The event is set to comprehensively map out the entire mRNA value chain—spanning drug design, delivery innovation, clinical translation, and commercial manufacture. By fostering scientific innovation and biopharma collaborations, the summit aims to accelerate emerging discoveries into scalable and clinically validated therapies.

The summit brings together key stakeholders across the global biopharma ecosystem. Alongside industry giants such as Novo Nordisk, Eli Lilly, Sanofi, and AstraZeneca, and pioneering biotechnology leaders like Moderna, the event will feature deep participation from multilateral organizations including the Coalition for Epidemic Preparedness Innovations (CEPI), as well as major global regulatory bodies such as the US FDA/CBER, Europe's EMA, and the UK's MHRA. More than a hundred corporate executives and scientific experts will gather to drive the innovation and application of mRNA technology in 2026 through focused panels, in-depth exchanges, and strategic collaborations.